PDL BioPharma Inc. (PDLI)

2.53
NASDAQ : Health Technology
Prev Close 2.60
Day Low/High 2.46 / 2.62
52 Wk Low/High 2.25 / 3.89
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 114.20M
Market Cap 296.93M
EPS -0.50
P/E Ratio 8.97
Div & Yield N.A. (N.A)
Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

PDL's sale and Pharmasset's Hep-C drew reader inquiries.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

This week: Biogen Idec and Synta.

Best Case for PDL BioPharma's Sale

The sum of the company's parts won't get shareholders their rightful value.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Health stocks were lower, despite ViaCell's buyout.

Microsoft Downplays Facebook Rumors

Microsoft Downplays Facebook Rumors

CEO Steve Ballmer called talk that the software giant was shopping for a stake 'idle speculation.'

Monday's Late Winners & Losers

Monday's Late Winners & Losers

PDL BioPharma jumped after saying its CEO left and it said it was exploring a sale.

Buffett Interested in Bear Stearns?

Rumors that the superinvestor and banks in Europe and China are eying a stake boosted the stock.

The Five Dumbest Things on Wall Street This Week: Quiz Answers

Thanks to all for playing.

The Five Dumbest Things on Wall Street This Week: Labor Day Quiz

The Five Dumbest Things on Wall Street This Week: Labor Day Quiz

Take a shot at winning a copy of Jim Cramer's latest book!

Activist Hedge Fund Lays Into PDL BioPharma

The activist hedge fund inks a letter calling for the departure of the company's chairman.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

PDL BioPharma sinks on a refocused business plan.

Tuesday's Late Winners & Losers

Tuesday's Late Winners & Losers

Semtech climbs on an earnings beat.

PDL BioPharma Refocuses

PDL BioPharma Refocuses

It will refocus on cancer and select immunological diseases and unload its Cardene, Retavase and IV Busulfex products.

Top Three Potential Short-Squeezes

Top Three Potential Short-Squeezes

One is NutriSystem, which raised its full-year outlook.

Tuesday's Health Winners & Losers

PDL BioPharma helped boost health care stocks Tuesday.

Traders Enjoy the Silence

A relative day of calm in the stock market is offset by wild times in Treasuries. John Roque of Natexis Bleichroeder and Chris Edmonds of ERC lend insights.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Health care stocks are flat, despite nice gains from Enzon and PDL BioPharma.

Jim Cramer's Stop Trading! Don't Buy Fannie Mae

Cramer wants to stay out of the mortgage space.

Stockpickr Lists: Could Sale Follow PDL CEO Ouster?

Mark McDade, long a target of major investor Third Point, is leaving. Is a sale far behind?

PDL BioPharma CEO to Step Down

Mark McDade, long a target of investor Third Point, will leave the drug company by the end of the year.

Stockpickr Lists: Intuitive Surgical Skyrockets

Stockpickr Lists: Intuitive Surgical Skyrockets

The surgical-robotics maker hit a 52-week high on heavy trading after an earnings blowout.

Top 12 Biotech Short Squeeze Stocks

Top 12 Biotech Short Squeeze Stocks

These could soar on positive news.

Third Point Lasers In On Tattoo Stocks

Third Point Lasers In On Tattoo Stocks

As tattooed baby boomers express regret, these stocks should clean up.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

Could Biogen Idec buy PDL BioPharma?;TNFerade doesn't spark confidence; YM BioSciences' nimotuzumab may be for real.

Thursday's Health Winners & Losers

MedcoHealth Solutions moves higher on news of a federal contract.

Tuesday's Health Winners & Losers

Celgene climbs on positive data for its oral anti-inflammatory agent.

Medicines Company Leaves Sour Taste

The company loses a key patent battle. Meanwhile, issues loom with its pipeline.

Stockpickr: Cramer's Portfolios of the Week

Check out the stocks that Jim has been talking about lately.

New! 'Mad Money' Culture Quiz

New! 'Mad Money' Culture Quiz

See how closely you paid attention to Cramer this week.

Stockpickr: Cramer's Portfolios of the Week

Stockpickr: Cramer's Portfolios of the Week

Reviewing portfolios built on his themes this week.

TheStreet Quant Rating: C- (Hold)